PAUL H KLINGENSTEIN

CIK 935463 · last filed 2021-06-11

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

32

Lifetime Open-Market Net

$12.41M

Filer Profile

Reported Address
428 UNIVERSITY AVE
C/O ACCEL PARTNERS
PALO ALTO, CA 94301
Related Filers
RANZETTA THERESIA GOUW — 4 joint filings, latest 2007-04-26
LUKE EVNIN — 3 joint filings, latest 2007-04-26
JAMES R SWARTZ — 1 joint filings, latest 2004-07-28
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Clovis Oncology, Inc. (CLVS) Delisted Director 72,082 $0.08 $5.9K $5.19M 11 2021-06-11
Histogen Inc. (CNAT) Delisted Director 2,905 $1.18M 2 2014-02-25
Anacor Pharmaceuticals, Inc. (ANAC) Delisted Director 382,976 $10.19 $3.90M $1.50M 5 2013-06-07
ReShape Weightloss Inc. (ETRM) Delisted Director 31,157 $4.54M 14 2013-05-10

Recent Filings · Page 2 of 4

32 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2013-06-17 Clovis Oncology, Inc. (CLVS) Delisted Grant (A) $0 EDGAR
2013-06-07 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Grant (A) $0 EDGAR
2013-05-10 ReShape Weightloss Inc. (ETRM) Delisted Grant (A) $0 EDGAR
2012-06-18 Clovis Oncology, Inc. (CLVS) Delisted Grant (A) $0 EDGAR
2012-06-01 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Grant (A) $0 EDGAR
2012-05-11 ReShape Weightloss Inc. (ETRM) Delisted Grant (A) $0 EDGAR
2012-03-22 Clovis Oncology, Inc. (CLVS) Delisted Mixed +1,303,665 $5.19M EDGAR
2011-05-26 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Grant (A) $0 EDGAR
2011-05-09 ReShape Weightloss Inc. (ETRM) Delisted Grant (A) $0 EDGAR
2011-04-04 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Grant (A) $0 EDGAR
Showing 1120 of 32
Page 2 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.